Fronto‐striatal damage may contribute to resistance to fatigue‐lowering medications in multiple sclerosis

Background and Purpose Commonly used fatigue‐lowering medications have not been proven effective in treating multiple sclerosis (MS)‐related fatigue. A neuroanatomical basis for treatment‐resistant fatigue in MS has not been explored. The aim of this study was to investigate the association between...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuroimaging 2023-03, Vol.33 (2), p.269-278
Main Authors: Palotai, Miklos, Pintye, Diana, Glanz, Bonnie, Chitnis, Tanuja, Guttmann, Charles R.G.
Format: Article
Language:English
Subjects:
Anatomy
Anisotropy
Anti-Anxiety Agents - therapeutic use
Antidepressants
Biomarkers
Brain
Brain architecture
Brain damage
Brain injury
brain MRI
Cross-Sectional Studies
Fatigue
fractional anisotropy
Humans
Modafinil
Modafinil - therapeutic use
Multiple sclerosis
Multiple Sclerosis - drug therapy
Neostriatum
Neuroimaging
Retrospective Studies
treatment resistance
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Purpose Commonly used fatigue‐lowering medications have not been proven effective in treating multiple sclerosis (MS)‐related fatigue. A neuroanatomical basis for treatment‐resistant fatigue in MS has not been explored. The aim of this study was to investigate the association between brain diffusion abnormality patterns and resistance to fatigue‐lowering treatment. Methods Retrospective patient stratification: 1. treatment‐resistant (n = 22) received anti‐fatigue and/or anti‐depressant and/or anxiolytic medication and the latest two Modified Fatigue Impact Scale (MFIS) score≥38; 2. responder (n = 16): received anti‐fatigue and/or antidepressant and/or anxiolytic medication while the latest MFIS was
ISSN:1051-2284
1552-6569
DOI:10.1111/jon.13082